Alto and Cencora are collaborating to deliver enhanced patient support services and streamline access to prescribed specialty medications. The collaboration leverages Cencora’s patient support ...

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $262.56 in the previous session.

Cencora Stock Up 1.2 % Shares of COR stock opened at $264.02 on Wednesday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $265.44. The stock has a market cap of $51.20 billion ...

Cencora has made headlines with its announcement on March 10, 2025, detailing plans for strategic acquisitions and investments in technology infrastructure, aiming to drive future growth.

Cencora COR has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

Cencora, formerly known as AmerisourceBergen, is one of the Big 3 drug distributors alongside peers McKesson Corporation (MCK) and Cardinal Health, Inc. (CAH). It provides pharmaceutical ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is updating its model following Cencora’s results and ...

Cencora, Inc. (NYSE:COR – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports.